The global human growth hormone treatment and drugs market exhibits a valuation of US$ 3.55 Billion by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 3.7%, and is expected to hold a market value of around US$ 5.26 Billion in 2033.
Market Outlook:
Data Points | Market Insights |
---|---|
Market Value 2022 | US$ 3.55 Billion |
Market Value 2023 | US$ 3.67 Billion |
Market Value 2033 | US$5.26 Billion |
CAGR 2023 to 2033 | 3.7% |
Market Share of Top 5 Countries (2022) | 48.7% |
Key Market Players | Ankebio Co. Ltd., Eli Lilly and Company, Emd Serono, Ferring Pharmaceuticals, Genentech Inc., Gene Science Pharmaceutical Co. Ltd., Ipsen, LG Life Sciences, Merck KGaA, Novo Nordisk, Ascendis Pharma, Pfizer Inc. |
Human growth hormone (hGH) also known as Somatotropin is a peptide hormone that is crucial for human development and is responsible for cell regeneration, cell reproduction, and growth stimulation. Growth hormone deficit results from the pituitary gland's inability to synthesise growth hormone (GH). Several inherited conditions, including Prader-Willi syndrome, Turner syndrome, and idiopathic short stature (ISS), which causes delayed puberty and shorter-than-average height, can also cause growth hormone insufficiency in humans.
Currently, hGH is frequently misused by bodybuilders, sportsmen, and older adults as an anti-aging medication and as a performance-enhancing anabolic substance. Growth hormone has not received USFDA approval for anti-aging or performance-enhancing uses because it is a prohibited substance.
Medication growth hormones are the suitable short-term treatments for such conditions, which are becoming more and more common among young people and elderly people alike worldwide. Medication for human growth hormone is readily available on the market today, raising awareness of its health benefits and helping manufacturing companies increase their revenue.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Human growth hormone treatment and drugs market expanded at a CAGR of 2.7% for 2017 to 2022 period due to growing incidences of growth hormone insufficiency, urban lifestyle and unhealthy food habits.
The market value for human growth hormone treatment and drugs was around 16.47% of the overall US$ 21.25 Billion of the global hormone replacement therapy market in 2022.
Due to increased research and development, increased healthcare expenditure, and improved healthcare infrastructure, the pharmaceutical and healthcare industries are rapidly expanding. Around the world, many hospitals, ambulatory surgical care centers, and clinics are installing cutting-edge devices and equipment.
Rising chronic disease prevalence, rapid advancements in the healthcare and medical sectors, widespread adoption of new tools and techniques, and increased funding from various public and private sectors are further, driving revenue growth in the global hormone replacement therapy market.
The advancement in human biomedical sciences and the discovery of new methods for synthesising long-acting second-generation products like growth hormones or somatotropin has brought down the human hormone growth injection price. This overall drop-in price has further boosted the growth of the human growth hormone treatment and drugs market globally.
Healthcare has undergone a digital revolution in the last decade. Rapid advancements in connected health, mobile technology, artificial intelligence (AI), and gamification, including virtual and augmented reality (VR/AR), are changing how patients are diagnosed, treated, and managed. Typically, digital health solutions are disease-specific and address specific conditions and patient populations.
Market Statistics | Details |
---|---|
Jan-Jun (H1), 2021 (A) | 2.50% |
Jul-Dec (H2), 2021 (A) | 3.19% |
Jan-Jun (H1),2022 Projected (P) | 2.40% |
Jan-Jun (H1),2022 Outlook (O) | 2.64% |
Jul-Dec (H2), 2022 Outlook (O) | 3.49% |
Jul-Dec (H2), 2022 Projected (P) | 3.17% |
Jan-Jun (H1), 2023 Projected (P) | 2.90% |
BPS Change : H1,2022 (O) - H1,2022 (P) | 25 ↑ |
BPS Change : H1,2022 (O) - H1,2021 (A) | 14 ↑ |
BPS Change: H2, 2022 (O) - H2, 2022 (P) | 32 ↑ |
BPS Change: H2, 2022 (O) - H2, 2022 (A) | 30 ↑ |
Urban lifestyles and deteriorating dietary habits leading to significant hormonal imbalance are expected to increase demand for human growth hormone drugs and a wide range of treatment options. Medication growth hormones assist in such situations and are thus, gaining popularity among both young and old people worldwide.
The market is further expected to grow due to a strenuous product pipeline and extensive research and development activities for the development of novel growth hormone therapies.
The market is also expected to be fuelled by a variety of public and private campaigns aimed at raising awareness of growth hormone deficiency and treatment options. The International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a non - profit organisation based in the United States, observes International Children's Growth Awareness Day each year to promote public understanding of the identification and management of growth hormone disorders and to aid in the rapid recovery of people, particularly children.
The use of growth hormone medication has been well established thanks to the efforts of healthcare sectors in every region. However, awareness to use of human growth hormones to treat many deficiency diseases among adults remains low, particularly in developing countries. This fact may significantly impede market participants from reaching their full potential.
In the market for treating growth hormone problems, complications are highly likely. Complications after the treatment include possible growth hormone therapy side effects, such as knee, hip, or other joint soreness; allergic reactions, such as hives, rash, or swelling; and an increase in blood sugar levels. As a result, it prevents the growth of the market.
The high cost of these medications restricts market expansion. Drugs for growth hormone disorders are expensive and may become costly for lower socioeconomic groups.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Country | The USA |
---|---|
Market Share (2023) | 25.9% |
Market Share (2033) | 24.9% |
BPS Analysis | -106 |
Country | China |
---|---|
Market Share (2023) | 6.6% |
Market Share (2033) | 6.8% |
BPS Analysis | 19 |
Country | Japan |
---|---|
Market Share (2023) | 5.9% |
Market Share (2033) | 6.3% |
BPS Analysis | 36 |
Country | Germany |
---|---|
Market Share (2023) | 5.0% |
Market Share (2033) | 4.6% |
BPS Analysis | -38 |
Country | Canada |
---|---|
Market Share (2023) | 4.9% |
Market Share (2033) | 5.0% |
BPS Analysis | 8 |
The USA is set to dominate the global human growth hormone treatment and drugs industry in 2023 with a market share of 25.9%.
The USA has a dominant position in the global market due to the presence of key players, primarily in the USA, who have expertise in manufacturing cutting-edge recombinant human growth hormone injections for the world's growing geriatric population.
According to the American Academy of Paediatrics, one in every 10,000 children in the USA suffers from growth hormone deficiency. Significant chronic and genetics conditions like Prader-Willi syndrome and Turner syndrome are rising. Thus, the increasing sale of growth hormone injections for the treatment of various growth disorders.
Germany is set to hold the largest sector share in Europe. Globally, Germany will hold around 5.0% revenue share in 2023.
The market for HGH medications in Germany is expected to grow due to a better understanding of growth hormonal diseases, a well-established health care infrastructure, and increased research and development, favorable reimbursement policies, and the region's established healthcare ecosystem.
According to the published article in the Deutsches Arzteblatt in 2011, Germany has developed a CrescNet System from last ten years in the Leipzig Treatment Center for early detection and awareness of growth hormone deficiency. Currently CrescNet System includes more than 323 medical practices and more than 22 pediatric endocrinology treatment centers with large number of doctors.
The China market will hold about 6.6% of the global market share in 2023.
The higher population count in China together with advanced research carried out in Chinese biotech companies are anticipated to boost the global market for Injectable human growth hormones at a higher growth rate.
According to a Biapharm in 2022 report, China has a large market for growth hormone products, which are required by around 7 million Chinese children for the treatment of short stature. HGH treatment for children is in high demand in China today, even when there is no medical abnormality. This has allowed domestic HGH manufacturers to expand while also attracting global pharmaceutical giants to the lucrative market.
Oral route of administration for leads the global market. In 2023, this segment is expected to hold about 43.3% within the global market.
Growth hormone deficiency in children is commonly perceived as a short height condition in boys and girls. Therefore, the human growth hormone pills for height are a popular oral product with huge growth potential during the forecast period.
The USA FDA (Food and Drug Administration) approved Macrilen (macimorelin) for oral administration in December 2017. This GH secretagogue receptor agonist is used to treat adult growth hormone deficiency (AGHD). Oral macimorelin administration is a simple, well tolerated, reproducible, and safe diagnostic test for AGHD, with the only reported side effect being bad taste.
Growth hormone deficiency (GHD) will lead the global market with the value share of about 27.7% in 2023.
As a broad category, growth hormone (GH) deficiency disease creates the most significant demand for human growth hormone shots in the healthcare sector. With the growing awareness among general population about the availability of treatment facilities and the discovery of new drugs, this segment is expected to hold the leading position for some more years ahead. Furthermore, GH deficiency in children is the major driving factor for this segment's human growth hormone treatment and drugs market.
Hospital pharmacies segment will hold the market share of 55.3% in 2023 globally.
Hormonal deficiency is a very serious concern for children and adults involves very complicated management of human growth hormone replacement therapy that skilled healthcare professionals in hospital setups must carry out. Attributing to this reason, the hospital pharmacy is the largest revenue generator for the global market accounting for more than about 50% of the stock volume of hGH human growth hormone injections for sale in the market.
Human Growth Hormone Treatment and Drugs Market:
Attributes | Human Growth Hormone Treatment and Drugs Market |
---|---|
CAGR (2023 to 2033) | 3.67% |
Market Value (2023) | US$ 3.67 Billion |
Growth Factor | Growing concern for the hormone deficiency disease in children as well as adults. Recombinant hormonal therapies have rationalized the cost of human growth hormone treatment. |
Key Market Trend | Standardization of medical procedures is propelling the online sales channel for human growth hormone drugs. |
Hormone Replacement Therapy Market:
Attributes | Hormone Replacement Therapy Market |
---|---|
CAGR (2023 to 2033) | 5.7% |
Market Value (2023) | US$ 15.8 Billion |
Growth Factor | Rising symptoms of post menopause disorder is predicted to grow the HRT market further in future. Rising proportion of geriatric population in North America and European countries is expected to create enough opportunities for rapid growth. |
Key Trend | Asia Pacific Region is attracting a lot of global players of HRT to establish manufacturing units there. |
Endocrine Testing Market:
Attributes | Endocrine Testing Market |
---|---|
CAGR (2023 to 2033) | 8.4% |
Market Value (2023) | US$ 2.7 Billion |
Growth Factor | Emerging endocrine disorders, self-testing pregnancy kits, and favorable government policies are likely to drive the growth of the endocrine testing market in the forecast period. |
Key Trend | Innovating therapies, technologies, and advancing diagnostic methods will contribute to the market's growth. |
Innovations in the field of designing new chemical formulations with greater efficiency is expected to increase the popularity of human growth hormone injections for adults in the market benefitting the market players. Key players within this space actively approaching mergers and acquisitions to expand their market reach and increase the volume of human growth hormone injections.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the human growth hormone treatment and drugs market, which are available in the full report.
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2017 to 2022 |
Market Analysis | US$ Million for Value |
Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa (MEA) |
Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC countries, Türkiye, South Africa and North Africa. |
Key Market Segments Covered | Route of Administration, Application, Distribution Channel, and Region |
Key Companies Profiled |
|
Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
Pricing | Available upon Request |
The market is expected to be valued at US$ 3.55 billion in 2023.
Until 2033, the market may rise at a 3.7% CAGR.
By 2033, the market may total around US$ 5.26 billion.
Sedentary lifestyle drives market expansion.
North America is expected to dominate the market until 2033.
1. Executive Summary | Human Growth Hormone Treatment and Drugs Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Market Innovation / Development Trends 4. Key Success Factors 4.1. Key Promotional Strategies, by Manufacturers 4.2. Key Regulations 4.3. PESTEL Analysis 4.4. Porter’s Analysis 4.5. Pipeline Assessment 4.6. Reimbursement 4.7. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Hormone Replacement Therapy Overview 5.2. Forecast Factors - Relevance and Impact 5.2.1. Top Companies Historical Growth 5.2.2. New Drug Launches and Approvals 5.2.3. Global Hormonal Diseases Epidemiology 5.2.4. RandD Expenditure by Key Players 5.2.5. Historic and Current Revenue of key players 5.2.6. Rising Consumer Awareness of the Treatment and Drugs 5.2.7. Increased Adoption of Hormonal Replacement Therapy for Various Hormonal Diseases 5.2.8. Strategic Collaborations among Players 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Route of Administration 6.1.2. By Application 6.1.3. By Distribution Channel 6.1.4. By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 7.2. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis by Route of Administration, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Route of Administration, 2023 to 2033 8.3.1. Subcutaneous 8.3.2. Intramuscular 8.3.3. Intravenous 8.3.4. Oral 8.4. Market Attractiveness Analysis by Route of Administration 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis by Application, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Application, 2023 to 2033 9.3.1. Growth Hormone Deficiency 9.3.2. Turner Syndrome 9.3.3. Idiopathic Short Stature (ISS) 9.3.4. Prader-Willi Syndrome (PWS) 9.3.5. Other Applications 9.4. Market Attractiveness Analysis by Application 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis by Distribution Channel, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Distribution Channel, 2023 to 2033 10.3.1. Hospital Pharmacy 10.3.2. Specialty Pharmacy 10.3.3. Retail Pharmacy 10.3.4. Online Pharmacy 10.4. Market Attractiveness Analysis by Distribution Channel 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, by Region, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. The Middle East and Africa 11.4. Market Attractiveness Analysis by Region 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. The USA 12.3.1.2. Canada 12.3.2. By Route of Administration 12.3.3. BY Application 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Route of Administration 12.4.3. By Application 12.4.4. By Distribution Channel 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis and Forecast 12.8.1. USA Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Route of Administration 12.8.1.2.2. By Application 12.8.1.2.3. By Distribution Channel 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Route of Administration 12.8.2.2.2. By Application 12.8.2.2.3. By Distribution Channel 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Route of Administration 13.3.3. By Application 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Route of Administration 13.4.3. By Application 13.4.4. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis and Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Route of Administration 13.8.1.2.2. By Application 13.8.1.2.3. By Distribution Channel 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Route of Administration 13.8.2.2.2. By Application 13.8.2.2.3. By Distribution Channel 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Route of Administration 13.8.3.2.2. By Application 13.8.3.2.3. By Distribution Channel 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. United Kingdom 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Route of Administration 14.3.3. By Application 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Route of Administration 14.4.3. By Application 14.4.4. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis and Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Route of Administration 14.8.1.2.2. By Application 14.8.1.2.3. By Distribution Channel 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Route of Administration 14.8.2.2.2. By Application 14.8.2.2.3. By Distribution Channel 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Route of Administration 14.8.3.2.2. By Application 14.8.3.2.3. By Distribution Channel 14.8.4. United Kingdom Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Route of Administration 14.8.4.2.2. By Application 14.8.4.2.3. By Distribution Channel 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Route of Administration 14.8.5.2.2. By Application 14.8.5.2.3. By Distribution Channel 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Route of Administration 14.8.6.2.2. By Application 14.8.6.2.3. By Distribution Channel 14.8.7. Russia Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Route of Administration 14.8.7.2.2. By Application 14.8.7.2.3. By Distribution Channel 15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Route of Administration 15.3.3. By Application 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Route of Administration 15.4.3. By Application 15.4.4. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis and Forecast 15.8.1. China Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Route of Administration 15.8.1.2.2. By Application 15.8.1.2.3. By Distribution Channel 15.8.2. Japan Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Route of Administration 15.8.2.2.2. By Application 15.8.2.2.3. By Distribution Channel 15.8.3. South Korea Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Route of Administration 15.8.3.2.2. By Application 15.8.3.2.3. By Distribution Channel 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Thailand 16.3.1.5. Rest of South Asia 16.3.2. By Route of Administration 16.3.3. By Application 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Route of Administration 16.4.3. By Application 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis and Forecast 16.8.1. India Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Route of Administration 16.8.1.2.2. By Application 16.8.1.2.3. By Distribution Channel 16.8.2. Indonesia Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Route of Administration 16.8.2.2.2. By Application 16.8.2.2.3. By Distribution Channel 16.8.3. Malaysia Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Route of Administration 16.8.3.2.2. By Application 16.8.3.2.3. By Distribution Channel 16.8.4. Thailand Market Analysis 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Route of Administration 16.8.4.2.2. By Application 16.8.4.2.3. By Distribution Channel 17. Oceania Market 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Route of Administration 17.3.3. By Application 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Route of Administration 17.4.2. By Application 17.4.3. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis and Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Route of Administration 17.8.1.2.2. By Application 17.8.1.2.3. By Distribution Channel 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Route of Administration 17.8.2.2.2. By Application 17.8.2.2.3. By Distribution Channel 18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Türkiye 18.3.1.3. North Africa 18.3.1.4. South Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Route of Administration 18.3.3. By Application 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Route of Administration 18.4.3. By Application 18.4.4. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis and Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Route of Administration 18.8.1.2.2. By Application 18.8.1.2.3. By Distribution Channel 18.8.2. Türkiye Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Route of Administration 18.8.2.2.2. By Application 18.8.2.2.3. By Distribution Channel 18.8.3. South Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Route of Administration 18.8.3.2.2. By Application 18.8.3.2.3. By Distribution Channel 18.8.4. North Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Route of Administration 18.8.4.2.2. By Application 18.8.4.2.3. By Distribution Channel 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Ankebio Co. Ltd. 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Sales Footprint 20.3.1.4. Key Financials 20.3.1.5. SWOT Analysis 20.3.1.6. Key Developments 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategy 20.3.1.7.2. Product Strategy 20.3.1.7.3. Channel Strategy 20.3.2. Eli Lilly and Company 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Sales Footprint 20.3.2.4. Key Financials 20.3.2.5. SWOT Analysis 20.3.2.6. Key Developments 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategy 20.3.2.7.2. Product Strategy 20.3.2.7.3. Channel Strategy 20.3.3. Emd Serono 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Sales Footprint 20.3.3.4. Key Financials 20.3.3.5. SWOT Analysis 20.3.3.6. Key Developments 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategy 20.3.3.7.2. Product Strategy 20.3.3.7.3. Channel Strategy 20.3.4. Feeing Pharmaceuticals 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Sales Footprint 20.3.4.4. Key Financials 20.3.4.5. SWOT Analysis 20.3.4.6. Key Developments 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategy 20.3.4.7.2. Product Strategy 20.3.4.7.3. Channel Strategy 20.3.5. Genentech Inc. 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Sales Footprint 20.3.5.4. Key Financials 20.3.5.5. SWOT Analysis 20.3.5.6. Key Developments 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategy 20.3.5.7.2. Product Strategy 20.3.5.7.3. Channel Strategy 20.3.6. Gene Science Pharmaceutical Co. Ltd. 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Sales Footprint 20.3.6.4. Key Financials 20.3.6.5. SWOT Analysis 20.3.6.6. Key Developments 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategy 20.3.6.7.2. Product Strategy 20.3.6.7.3. Channel Strategy 20.3.7. Ipsen 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Sales Footprint 20.3.7.4. Key Financials 20.3.7.5. SWOT Analysis 20.3.7.6. Key Developments 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategy 20.3.7.7.2. Product Strategy 20.3.7.7.3. Channel Strategy 20.3.8. LG Life Sciences 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Sales Footprint 20.3.8.4. Key Financials 20.3.8.5. SWOT Analysis 20.3.8.6. Key Developments 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategy 20.3.8.7.2. Product Strategy 20.3.8.7.3. Channel Strategy 20.3.9. Merck KGaA 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Sales Footprint 20.3.9.4. Key Financials 20.3.9.5. SWOT Analysis 20.3.9.6. Key Developments 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategy 20.3.9.7.2. Product Strategy 20.3.9.7.3. Channel Strategy 20.3.10. Novo Nordisk 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Sales Footprint 20.3.10.4. Key Financials 20.3.10.5. SWOT Analysis 20.3.10.6. Key Developments 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategy 20.3.10.7.2. Product Strategy 20.3.10.7.3. Channel Strategy 20.3.11. Ascendis Pharma 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Sales Footprint 20.3.11.4. Key Financials 20.3.11.5. SWOT Analysis 20.3.11.6. Key Developments 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategy 20.3.11.7.2. Product Strategy 20.3.11.7.3. Channel Strategy 20.3.12. Pfizer Inc. 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Sales Footprint 20.3.12.4. Key Financials 20.3.12.5. SWOT Analysis 20.3.12.6. Key Developments 20.3.12.7. Strategy Overview 20.3.12.7.1. Marketing Strategy 20.3.12.7.2. Product Strategy 20.3.12.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports